Trial
NCT03777124
Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Collaborators
Shanghai Chest Hospital
Condition
NSCLC Stage IV
Intervention
SHR-1210
Why stopped
The sponsor's R\&D strategy is adjusted.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-04